EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of a Novel Hops (8-Prenylnaringenin) and Cimicifuga-Based Combination Food Supplement in Alleviating Climacteric Symptoms and Enhancing Quality of Life in Postmenopausal Women: Results from the LIBIRTY Clinical Study

Santiago Palacios Gil-Antuñano, Marieta Ramírez Bermúdez, María Teresa Martín Pedraza, Esther de la Viuda García, Mariella Lilue Bajares

Clinics and Practice · 18.11.2026 · 16 (11) · 217

DOI: 10.3390/clinpract16110217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinics and Practice, online erschienen am 18.11.2026. Verfasst von Santiago Palacios Gil-Antuñano und 4 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Procare Health Iberia S.L..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Menopause is associated with symptoms that may negatively affect quality of life (QoL). This study evaluated the effects of a Hops (8-prenylnaringenin, 8-PN) and Cimicifuga-based multicomponent food supplement on menopausal symptoms and QoL in postmenopausal women.

Methods

A prospective, unicentric, non-comparative, observational study was conducted in postmenopausal women aged 45–65 years with climacteric symptoms. Participants received two daily capsules (one DAY and one NIGHT) of a Hops (8-PN) and Cimicifuga-based food supplement (Libicare® Meno) for 12 weeks. QoL was assessed using the Cervantes short-form (C-SF) scale as the primary endpoint. Secondary endpoints included evaluation of general health status (EUROQOL), mood (Visual Analog Scale [VAS]), plasma vitamin D levels, satisfaction, and tolerability. Assessments were performed at baseline, 4, and 12 weeks.

Results

Thirty-three women were evaluated. Total C-SF score decreased from 41.13 ± 20.2 at baseline to 36.37 ± 21.5 and 33.70 ± 18.6 at 4 and 12 weeks, respectively, reaching statistical significance at week 12 (p = 0.046). The improvement was particularly evident in the vasomotor subdomain. Mood also improved significantly, with VAS scores decreasing from 5.18 ± 2.7 to 3.12 ± 2.2 (p = 0.001) and 3.30 ± 1.9 (p < 0.001) at 4 and 12 weeks, respectively. Vitamin D levels increased from 26.57 ± 8.22 to 32.75 ± 5.65 ng/mL at week 12. No serious adverse events were reported, and 51.5% of participants were satisfied or very satisfied with treatment.

Conclusions

Libicare® Meno was associated with improvements in QoL and mood in symptomatic postmenopausal women, with good tolerability and satisfaction.

Förderung

  • Procare Health Iberia S.L.

Zitieren

APA

Gil-Antuñano, S. P., Bermúdez, M. R., Pedraza, M. T. M., García, E. D. L. V., & Bajares, M. L. (2026). Effectiveness of a Novel Hops (8-Prenylnaringenin) and Cimicifuga-Based Combination Food Supplement in Alleviating Climacteric Symptoms and Enhancing Quality of Life in Postmenopausal Women: Results from the LIBIRTY Clinical Study. Clinics and Practice, 16(11), 217. https://doi.org/10.3390/clinpract16110217

Vancouver

Gil-Antuñano SP, Bermúdez MR, Pedraza MTM, García EDLV, Bajares ML. Effectiveness of a Novel Hops (8-Prenylnaringenin) and Cimicifuga-Based Combination Food Supplement in Alleviating Climacteric Symptoms and Enhancing Quality of Life in Postmenopausal Women: Results from the LIBIRTY Clinical Study. Clinics and Practice. 2026;16(11):217. doi:10.3390/clinpract16110217

BibTeX
@article{GilAntuano2026,
  author = {Gil-Antuñano, Santiago Palacios and Bermúdez, Marieta Ramírez and Pedraza, María Teresa Martín and García, Esther de la Viuda and Bajares, Mariella Lilue},
  title = {Effectiveness of a Novel Hops (8-Prenylnaringenin) and Cimicifuga-Based Combination Food Supplement in Alleviating Climacteric Symptoms and Enhancing Quality of Life in Postmenopausal Women: Results from the LIBIRTY Clinical Study},
  journal = {Clinics and Practice},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {217},
  doi = {10.3390/clinpract16110217}
}
Kostenlos starten →